Orasis Pharmaceuticals Ltd.
๐ฎ๐ฑIsrael
- Country
- ๐ฎ๐ฑIsrael
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.orasis-pharma.com
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 178
- Registration Number
- NCT05393895
- Locations
- ๐บ๐ธ
Orasis Investigative Site, Cedar Park, Texas, United States
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 304
- Registration Number
- NCT04599972
- Locations
- ๐บ๐ธ
Orasis Investigative Site, Lynchburg, Virginia, United States
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 309
- Registration Number
- NCT04599933
- Locations
- ๐บ๐ธ
Orasis Investigative Site, El Paso, Texas, United States
A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia
Phase 2
Completed
- Conditions
- Presbyopia
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT03885011
- Locations
- ๐บ๐ธ
Orasis Investigative Site, Draper, Utah, United States
Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
Phase 2
Completed
- Conditions
- Presbyopia
- Interventions
- Drug: PresbiDrops (CSF-1)Drug: Placebo
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02965664
- Locations
- ๐ฎ๐ฑ
The Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel
๐ฎ๐ฑOphthalmology Department, Western Galilee Medical Center, Nahariya, Israel
Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia
Phase 2
Completed
- Conditions
- Presbyopia
- Interventions
- Drug: PresbiDrops (CSF-1)Drug: Placebo
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02745223
- Locations
- ๐ฎ๐ฑ
The Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel
ยฉ Copyright 2025. All Rights Reserved by MedPath